dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Iranzo Gómez, Patricia |
dc.contributor.author | Callejo Perez, Ana |
dc.contributor.author | Assaf Pastrana, Juan David |
dc.contributor.author | Molina, Gaspar |
dc.contributor.author | Lopez, Daniel Esteban |
dc.contributor.author | García Illescas, David |
dc.contributor.author | Pardo Aranda, Nuria |
dc.contributor.author | Navarro Mendivil, Alejandro |
dc.contributor.author | Martínez Marti, Alexandre |
dc.contributor.author | Cedres Perez, Susana |
dc.contributor.author | Amat, Ramon |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Carbonell, Caterina |
dc.contributor.author | Frigola Rissech, Joan |
dc.date.accessioned | 2022-09-12T09:14:36Z |
dc.date.available | 2022-09-12T09:14:36Z |
dc.date.issued | 2022-05-30 |
dc.identifier.citation | Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, et al. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med. 2022 May 30;9:875974. |
dc.identifier.issn | 2296-858X |
dc.identifier.uri | https://hdl.handle.net/11351/8145 |
dc.description | Corticoides; Eficàcia; Inhibidors del punt de control immunitari |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Medicine;9 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Immunoteràpia |
dc.subject | Medicaments - Efectes secundaris |
dc.subject | Càncer - Complicacions |
dc.subject.mesh | Antineoplastic Agents, Immunological |
dc.subject.mesh | /adverse effects |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /therapy |
dc.title | Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fmed.2022.875974 |
dc.subject.decs | inmunoterapia antineoplásica |
dc.subject.decs | /efectos adversos |
dc.subject.decs | neoplasias |
dc.subject.decs | /terapia |
dc.relation.publishversion | https://doi.org/10.3389/fmed.2022.875974 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, Pardo N, Navarro A, Martinez-Marti A, Cedres S, Felip E] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Carbonell C, Frigola J, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 35707528 |
dc.identifier.wos | 000811872600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |